Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Patent
1995-06-06
1999-02-02
Scheiner, Laurie
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
536 2372, 4241881, 4242081, 4241991, 4242021, 435236, C12Q 170, C12N 704, C07H 2104, A61K 3912
Patent
active
058663207
ABSTRACT:
Non-infectious, retrovirus-like particles comprise an assembly of an env gene product, a pol gene product and a gag gene product contain an antigenic marker which is non-retroviral or non-HIV retroviral. In one embodiment, the marker comprises an amino acid sequence containing an epitope inserted into the gag gene product at an antigenically-active insertion site. In another embodiment, the marker comprises an antigenic anchor sequence operatively connected to the env gene product replacing endogenous anchoring function. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis. The presence of the antigenic marker enables recognition that antiserum containing anti-retroviral antibodies has been generated by exposure to the non-infectious retrovirus-like particles by testing for antibodies specific to the antigenic marker.
REFERENCES:
patent: 5352449 (1994-10-01), Beltz et al.
Rovinski, B., et al, J. Virol. (1992), 66(7), 4003-12, Jul. 1992--"Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine".
Klein, M., AIDS Research and Human Retroviruses--vol. 10--Supplement 1, Aug. 1994--"Neutralizing activities of HIV-1 pseudovirons and T-B tandem epitopes".
Haynes, J.R. et al, The Vaccine Symposium, Toronto, Ontario, Canada, Oct. 1989. Molecular Immun. 28(3) 1991. Pp. 231-234, "Strategy for Developing a Genetically-Engineered Whole-Virus Vaccine Against HIV".
Karacostas, V. Et al, Proceedings of the National Academy of Sciences of the USA, vol. 86, No. 22, Nov. 1, 1989, "Immunodeficiency Virus-Like Particles Produced by a Vaccinia Virus Expression Vector".
Yao-, Fei-Long et al, Biotechniques (1995), 18(3), pp. 372, 374--Mar. 1995, Gene assembly-aided mutagenesis (GAAM).
Hunter, 1994, Sem. Virol. 5:71-83.
Karacostas et al., 1993, Virol. 193:661-671.
Rovinski et al., 1992, J. Virol. 66:4003-4012.
Perkins et al., 1991, J. Immunol. 146:2137-2144.
Sharma et al., 1993, Vaccine, 11:1321-1326.
Haynes et al., 1991, AIDS Res. Human Retro. 7:17-27.
Trifilieff et al., 1991, Mol. Immunol. 28:889-896.
Ohno et al., 1984, J. Biochem. 96:1915-1923.
Wain-Hobson et al Cell, vol. 40, 9-17, Jan. 1985.
Rovinski et al, J. of Virology, Jul. 1992, pp. 4003-4012, vol.66, No.7.
Allzon et al, 1984.
Min Jou et al, Cell, vol. 19, 683-696, Mar. 1980.
Myers et al, Human Retroviruses and Aids 1988.
Trifilleff et al, Molecular Immunology, vol. 28, No. 8, pp. 889-896, 1991.
Ulmer et al, 1993 Current Drugs Ltd. ISSN 0967-8298.
Westhof et al, Nature, vol. 311, 13 Sep. 1984, 123-1260.
Cao Shi-Xian
Klein Michel H.
Persson Roy
Rovinski Benjamin
Yao Fei-Long
Connaught Laboratories Limited
Parkin Jeffrey S.
Scheiner Laurie
LandOfFree
Nucleic acids encoding for non-infectious, replication-defective does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding for non-infectious, replication-defective, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding for non-infectious, replication-defective will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1115982